INTRODUCTION: Bevacizumab is increasingly being tested with neoadjuvant regimens in patients with localized cancer, but its effects on metastasis and survival remain unknown. This study examines the long-term outcome of clinical stage II/III rectal cancer patients treated in a prospective phase II study of bevacizumab with chemoradiation and surgery. As a benchmark, we used data from an analysis of 42 patients with locally advanced rectal cancer treated with a contemporary approach of preoperative fluoropyrimidine-based radiation therapy. MATERIALS AND METHODS: Outcome analyses were performed on 32 patients treated prospectively with neoadjuvant bevacizumab, 5-fluorouracil, radiation therapy, and surgery as well as 42 patients treated with standard fluoropyrimidine-based chemoradiation. RESULTS: Overall survival, disease-free survival, and local control showed favorable trends in patients treated with bevacizumab with chemoradiation followed by surgery. Acute and postoperative toxicity appeared acceptable. CONCLUSIONS: Neoadjuvant bevacizumab with standard chemoradiation and surgery shows promising long-term efficacy and safety profiles in locally advanced rectal cancer patients.
INTRODUCTION:Bevacizumab is increasingly being tested with neoadjuvant regimens in patients with localized cancer, but its effects on metastasis and survival remain unknown. This study examines the long-term outcome of clinical stage II/III rectal cancerpatients treated in a prospective phase II study of bevacizumab with chemoradiation and surgery. As a benchmark, we used data from an analysis of 42 patients with locally advanced rectal cancer treated with a contemporary approach of preoperative fluoropyrimidine-based radiation therapy. MATERIALS AND METHODS: Outcome analyses were performed on 32 patients treated prospectively with neoadjuvant bevacizumab, 5-fluorouracil, radiation therapy, and surgery as well as 42 patients treated with standard fluoropyrimidine-based chemoradiation. RESULTS: Overall survival, disease-free survival, and local control showed favorable trends in patients treated with bevacizumab with chemoradiation followed by surgery. Acute and postoperative toxicity appeared acceptable. CONCLUSIONS: Neoadjuvant bevacizumab with standard chemoradiation and surgery shows promising long-term efficacy and safety profiles in locally advanced rectal cancerpatients.
Authors: Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab Journal: N Engl J Med Date: 2004-10-21 Impact factor: 91.245
Authors: Christopher G Willett; Yves Boucher; Dan G Duda; Emmanuelle di Tomaso; Lance L Munn; Ricky T Tong; Sergey V Kozin; Lucine Petit; Rakesh K Jain; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Kenneth S Cohen; David T Scadden; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Paul C Shellito; Mari Mino-Kenudson; Gregory Y Lauwers Journal: J Clin Oncol Date: 2005-11-01 Impact factor: 44.544
Authors: Dan G Duda; Christopher G Willett; Marek Ancukiewicz; Emmanuelle di Tomaso; Mira Shah; Brian G Czito; Rex Bentley; Martin Poleski; Gregory Y Lauwers; Madeline Carroll; Douglas Tyler; Christopher Mantyh; Paul Shellito; Jeffrey W Clark; Rakesh K Jain Journal: Oncologist Date: 2010-05-18
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain Journal: Nat Med Date: 2004-01-25 Impact factor: 53.440
Authors: Bruce J Giantonio; Paul J Catalano; Neal J Meropol; Peter J O'Dwyer; Edith P Mitchell; Steven R Alberts; Michael A Schwartz; Al B Benson Journal: J Clin Oncol Date: 2007-04-20 Impact factor: 44.544
Authors: Timothy P Padera; Angera H Kuo; Tohru Hoshida; Shan Liao; Jennifer Lobo; Kevin R Kozak; Dai Fukumura; Rakesh K Jain Journal: Mol Cancer Ther Date: 2008-08-06 Impact factor: 6.261
Authors: Han-Sin Jeong; Dennis Jones; Shan Liao; Daniel A Wattson; Cheryl H Cui; Dan G Duda; Christopher G Willett; Rakesh K Jain; Timothy P Padera Journal: J Natl Cancer Inst Date: 2015-06-10 Impact factor: 13.506
Authors: Dan G Duda; Sergey V Kozin; Nathaniel D Kirkpatrick; Lei Xu; Dai Fukumura; Rakesh K Jain Journal: Clin Cancer Res Date: 2011-02-24 Impact factor: 12.531
Authors: Shom Goel; Dan G Duda; Lei Xu; Lance L Munn; Yves Boucher; Dai Fukumura; Rakesh K Jain Journal: Physiol Rev Date: 2011-07 Impact factor: 37.312
Authors: Sachie Hiratsuka; Dan G Duda; Yuhui Huang; Shom Goel; Tatsuki Sugiyama; Takashi Nagasawa; Dai Fukumura; Rakesh K Jain Journal: Proc Natl Acad Sci U S A Date: 2010-12-20 Impact factor: 11.205